Catabasis Pharmaceuticals

Catabasis Pharmaceuticals
Public
Traded as NASDAQ: CATB
Industry Pharmaceuticals
Headquarters Cambridge, Massachusetts
Key people

Jill C. Milne, Ph.D. (Co-founder and CEO) Michael Jirousek, Ph.D. (Co-founder and CSO) Chris Thomajan (CFO) Joanne M. Donovan, M.D., Ph.D. (CMO) Michael Curtis, Ph.D. (SVP, Product Development and Regulatory Affairs)

Henry Rath, M.B.A. (VP, Business Development)
Products Orally-delivered pharmaceuticals
Number of employees
 34 (June 2015)
Website www.catabasis.com

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously.[1] Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.

Catabasis has two programs in clinical development. CAT-2003, a conjugate of the B vitamin niacin and the omega-3 fatty acid eicosapentaenoic acid (EPA), is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing.[2] CAT-1004 (Edasalonexent), a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, has completed Phase 1 testing;[3] the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and Duchenne muscular dystrophy. In the Phase 1 study, results showed that CAT-1004 was safe and well tolerated,and that the linker technology allowed the active components to inhibit the NF-kB pathway synergistically;,[4][5] this pathway plays an important role in inflammation.[6]

References

  1. ↑ 1Hendriks, BS. (2010). Functional pathway pharmacology: chemical tools, pathway knowledge and mechanistic model-based interpretation of experimental data. Current Opinion in Chemical Biology, 14(4), 489-97. doi: 10.1016/j.cbpa.2010.06.167.
  2. ↑ 2Clinicaltrial.gov A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 http://clinicaltrials.gov/ct2/show/NCT01725594?term=CAT-2003&rank=1
  3. ↑ 3Clinicaltrial.gov A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes http://clinicaltrials.gov/ct2/show/NCT01511900?term=CAT-1004&rank=1 Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers http://clinicaltrials.gov/ct2/show/NCT01440166?term=CAT-1004&rank=2 A Study of CAT-1004 Biomarkers in Healthy Subjects http://clinicaltrials.gov/ct2/showqaq/NCT01670773?term=CAT-1004&rank=3
  4. ↑ 4BioFlash (Mass High Tech) Catabasis sees positive Phase 1 data (2/11/13) http://www.bizjournals.com/boston/blog/bioflash/2013/02/catabasis-sees-positive-phase-1-data.html
  5. ↑ 5Xconomy Catabasis Passes First Trials With Anti-Inflammatory Drug (2/11/13) http://www.xconomy.com/boston/2013/02/11/catabasis-passes-first-trials-with-anti-inflammatory-drug/
  6. ↑ 6Tieri P, Termanini A, Bellavista E, Salvioli S, Capri M, et al. (2012). Charting the NF-κB Pathway Interactome Map. PLoS ONE 7(3), e32678. doi:10.1371/journal.pone.0032678
This article is issued from Wikipedia - version of the 10/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.